Modality
Bispecific Ab
MOA
PARPi
Target
WRN
Pathway
Proteasome
FSGS
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
Jan 2017
→ Jan 2026
Phase 2Current
NCT05964500
2,546 pts·FSGS
2017-01→2026-01·Active
2,546 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-172mo agoPh2 Data· FSGS
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P2
Active
Catalysts
Ph2 Data
2026-01-17 · 2mo ago
FSGS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05964500 | Phase 2 | FSGS | Active | 2546 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 |